VT
VistaGen Therapeutics, Inc.
VTGN · NASDAQ
$0.28 -8.19% (-$0.03)
1M +14.88%
Market Cap $12.5M
P/E Ratio -
Div. Yield -
ROE 152.59%
Bulios Fair Price
$0.36
27.4% upside
Current Price
$0.28
Undervalued Fair Value Overvalued
According to Bulios Fair Price, VTGN is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
68 /100
Cheap P/B 0.51x
P/S 5.01x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 43.26%
FCF growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 2,784.33%
Gross margin 84.57%
FCF margin 2,489.89%
Quality
1 /100
Poor ROA 189.22%
ROIC 275.77%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 3.07x
Debt/Equity 0.03x
Debt/Assets N/A
Stability
23 /100
Unstable EPS volatility 53.04%
Beta 0.39x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about VTGN
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Shawn K. Singh
Employees
41
Headquarters
South San Francisco
Upcoming events
12 NOV
Earnings
Upcoming earnings report